| 前列腺切除术前应用爱普列特临床疗效的Meta分析 |
| 投稿时间：2014-11-13 修订日期：2014-11-27 点此下载全文 |
| 引用本文：陈勇伟,龚小新,杨勇,王晓康,姚启盛.前列腺切除术前应用爱普列特临床疗效的Meta分析[J].医学研究杂志,2015,44(6):138-142 |
| DOI：
10.11969/j.issn.1673-548X.2015.06.039 |
| 摘要点击次数: 993 |
| 全文下载次数: 683 |
|
|
| 中文摘要:目的 探讨良性前列腺增生患者术前应用爱普列特对于手术的临床疗效。方法 通过检索自1994年1月~2014年1月期间万方数据库(CECDB)、维普中文科技期刊数据库(CQVIP)、中国学术期刊数据库(CNKI)、考克兰图书馆(The Cochrane Library)、西文生物医学期刊数据库(EMCC)、荷兰医学文摘数据库(EMbase)、学术期刊集成数据库(ASP)、美国国立医学图书馆(PubMed)等数据库内相关的随机对照试验(RCT),对纳入文献的质量进行严格评价和资料提取,使用Stata/SE version 12.0软件对纳入研究进行Meta分析。结果 最终纳入8篇RCT,共644例患者,其中实验组患者341例、对照组患者303例。实验组患者实施爱普列特、对照组为空白对照组。Meta分析结果显示:相比对照组患者,术前应用爱普列特的前列腺增生患者,其术中出血量显著降低:1等离子电切术亚组(P=0.314,I2=15.5%,SMD=-0.57,95%CI:-0.81~-0.34);2汽化电切术亚组(P=0.100,I2=42.9%,SMD=-2.70,95%CI:-4.22~-0.97)。其结果稳健:1等离子电切术亚组(bias_P=0.142,bias_95 CI:-31.54348~9.208739);2汽化电切术亚组(bias_P=0.945,bias_95 CI:-14.27004~14.79971)。但对于术中前列腺腺体的切除重量,Meta分析差异无统计学意义(P=0.578,I2=0%,SMD=-0.02,95%CI:-0.23~0.18)。结论 前列腺增生患者术前应用爱普列特,能够有效显著降低患者的术中出血量,其疗效确切,值得临床推广。 |
| 中文关键词:爱普列特 经尿道前列腺切除术 良性前列腺增生症 5-α还原酶抑制剂 Meta分析 |
| |
| Effect of Clinical Efficacy Before Prostatectomy Surgery Using Epristeride:Meta-analysis |
|
|
| Abstract:Objective To investigate the clinical efficacy of benign prostatic hyperplasia patients using epristeride before surgery. Methods By searching the RCT CECDB、CQVIP、CNKI、The Cochrane Library、EMCC、EMbase、ASP、PubMed in 1994 January to 2014 January period, strict appraisal and data extraction on the quality of the included studies, using Stata/SE version 12 software systematic evaluation of included studies. Results Eventually included eight RCT, a total of 644 cases of patients,and then the experimental group including 341 cases of patients who were using the epristeride before surgery while the control group including patients 303 cases who were not. Meta-analysis showed that: compared with the control group, the intraoperative blood loss of the patients with benign prostatic hyperplasia using epristeride before surgery was significantly reduced: 1Plasma TURP subgroups (P=0.314, I2=15.5%, SMD=-0.57, 95% CI:-0.81--0.34); 2transurethral resection subgroups(P=0.100, I2=42.9%, SMD=-2.70,95% CI:-4.22--0.97). The results are robust: 1Plasma TURP subgroups(bias_P=0.142, bias_95 CI:-31.54348-9.208739); 2transurethral resection subgroups(bias_P=0.945, bias_95 CI:-14.27004-14.79971). But for the weight of the removal prostate gland, Meta-analysis shows no significant difference(P=0.578,I2=0%, SMD=-0.02,95% CI:-0.23-0.18). Conclusion Using epristeride before surgery of the prostatic hyperplasia patients can reduce the intraoperative blood loss significantly, the efficacy is definitely, worthy of clinical promotion. |
| keywords:Epristeride Transurethral resection of prostate Benign prostatic hypertrophy 5-α Reductase suppressors Meta-analysis |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|
